Cellectis SA (CMVLF)
OTHER OTC:CMVLF
CMVLF Stock Chart & Stats
$4.40
-$0.25(-16.67%)
At close: 4:00 PM EST
$4.40
-$0.25(-16.67%)
Day’s Range― - ―
52-Week Range$1.25 - $5.04
Previous CloseN/A
Volume1.60K
Average Volume (3M)6.00
Market Cap
$201.89M
Enterprise Value$302.14M
Total Cash (Recent Filing)$185.47M
Total Debt (Recent Filing)$108.49M
Price to Earnings (P/E)―
Beta-0.39
Next Earnings
Jul 30, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding72,325,455
10 Day Avg. Volume20
30 Day Avg. Volume6
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)6.52
Price to Sales (P/S)6.52
P/FCF Ratio-11.22
Enterprise Value/Market Cap1.50
Enterprise Value/Revenue4.44
Enterprise Value/Gross Profit5.63
Enterprise Value/Ebitda-6.73
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.89
Revenue Forecast (FY)$59.27M
Bulls Say, Bears Say
Bulls Say
Platform & PipelineCellectis’ focus on gene-edited, allogeneic T‑cell therapies is a structural competitive advantage: off‑the‑shelf products can scale manufacturing, broaden patient access, and lower per‑patient costs versus autologous cells, creating durable commercial optionality if clinical success follows.
High Gross MarginsSustained high gross margins indicate favorable unit economics from technology licensing, services or product components; this supports attractive long‑term profitability potential if operating expenses are scaled appropriately or partner revenues expand, improving resilience once revenues grow.
Collaboration-driven Revenue ModelA partner‑centric revenue model provides diversified, non‑product income (upfronts, milestones, R&D reimbursements), lowering commercialization risk and enabling development funding without immediate product sales; structurally this reduces single‑asset dependence and aligns incentives with partners.
Bears Say
Cash Burn & Negative Cash FlowPersistent negative operating and free cash flow creates ongoing financing needs; over a multi‑month horizon this increases reliance on external capital, risks dilution or costly debt, and can constrain R&D pacing and program advancement if new funding terms are unfavorable.
Rising Leverage & Shrinking EquityIncreasing leverage and falling equity weaken financial flexibility: higher debt amplifies interest and covenant exposure, reduces capacity for opportunistic investment, and heightens refinancing risk—especially important for clinical‑stage biotech with variable cash needs.
Deeply Negative ProfitabilityVery large negative margins reflect operating costs far above current revenue; structurally this limits the company’s ability to self‑fund growth or sustain programs without partner funding, and prolongs dependency on external financing until clinical progress materially improves revenue prospects.
Cellectis SA News
CMVLF FAQ
What was Cellectis SA’s price range in the past 12 months?
Cellectis SA lowest stock price was $1.25 and its highest was $5.04 in the past 12 months.
What is Cellectis SA’s market cap?
Cellectis SA’s market cap is $201.89M.
When is Cellectis SA’s upcoming earnings report date?
Cellectis SA’s upcoming earnings report date is Jul 30, 2026 which is in 31 days.
How were Cellectis SA’s earnings last quarter?
Cellectis SA released its earnings results on May 11, 2026. The company reported -$0.177 earnings per share for the quarter, beating the consensus estimate of -$0.256 by $0.079.
Is Cellectis SA overvalued?
According to Wall Street analysts Cellectis SA’s price is currently Overvalued.
Does Cellectis SA pay dividends?
Cellectis SA does not currently pay dividends.
What is Cellectis SA’s EPS estimate?
Cellectis SA’s EPS estimate is -0.26.
How many shares outstanding does Cellectis SA have?
Cellectis SA has 72,325,455 shares outstanding.
What happened to Cellectis SA’s price movement after its last earnings report?
Cellectis SA reported an EPS of -$0.177 in its last earnings report, beating expectations of -$0.256. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cellectis SA?
Currently, no hedge funds are holding shares in CMVLF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cellectis SA
Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and headquartered in Paris, France, concentrates on immuno-oncology. The firm engineers therapeutic solutions utilizing gene-edited T-cells, which are modified to display chimeric antigen receptors (CARs) for the specific identification and destruction of cancer cells. Its operations are divided into two principal segments: Therapeutics and Plants. The company's pipeline features several allogeneic CAR T-cell product candidates. These include UCART19, aimed at CD19-expressing hematologic malignancies such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A, developed to treat relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316, targeting renal cell carcinoma; UCART123, for acute myeloid leukemia; and UCART22, addressing B-cell acute lymphoblastic leukemia. Additionally, Cellectis is advancing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. Cellectis has forged significant strategic partnerships and alliances with companies including Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. It also maintains a strategic research and development collaboration with Cytovia Therapeutics, Inc.
CMVLF Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in advancing pivotal clinical trials and maintaining a strong financial position, with ongoing collaborations and upcoming strategic events. However, ongoing arbitration and a decrease in cash reserves posed challenges.View all CMVLF earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
0.02% Other Institutional Investors
99.98% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---